Previous 10 | Next 10 |
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced an upcoming presentation from the Phase 1b trial of botensilimab in combination with balstilimab (“BOT/BAL”) in patients with relapsed/ref...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its first quarter 2024 financial results before the market opens on Tuesday, May 7, 2024. Agenus executives will host a confere...
2024-04-12 09:11:16 ET More on Agenus Agenus Inc. (AGEN) Q4 2023 Earnings Call Transcript Agenus: A Would-Be Rockstar Held Back By Middling Financials Agenus: Taking Advantage Of The Risk-Reward Opportunity Agenus announces reverse stock split of common stock...
Updated Phase 1 data demonstrate a 12-month overall survival (OS) of 71% and 18-month OS of 62% Company plans to discuss encouraging Phase 2 interim results with the FDA Company plans to submit Phase 2 data to a major medical conference in the second half of 2024 Agenu...
2024-04-08 03:34:00 ET The past nine months have been rough ones to be an Agenus (NASDAQ: AGEN) shareholder. The stock has collapsed by about 75% from the peak it set last June. Investment bank analysts on Wall Street who follow the Massachusetts-headquartered cancer drug develo...
2024-04-05 16:39:30 ET More on Agenus Agenus Inc. (AGEN) Q4 2023 Earnings Call Transcript Agenus: A Would-Be Rockstar Held Back By Middling Financials Agenus: Taking Advantage Of The Risk-Reward Opportunity Agenus Q4 2023 Earnings Preview Ginkgo, Agen...
Agenus Inc. (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced its stockholders have approved a one-for-twenty reverse stock split of its issued and outstanding common stock, which will go into effect at 12:01 a.m., Eastern ...
2024-04-03 04:19:00 ET Investors looking for stocks that can produce dramatic gains over the next 12 months want to turn their attention to the biotechnology industry. Wall Street analysts tasked with following a synthetic biology company called Ginkgo Bioworks (NYSE: DNA) think it ...
2024-03-14 13:30:17 ET Image source: The Motley Fool. Agenus (NASDAQ: AGEN) Q4 2023 Earnings Call Mar 14, 2024 , 8:30 a.m. ET Operator Continue reading For further details see: Agenus (AGEN) Q4 2023 Earnings Call Transcript
2024-03-14 11:57:11 ET Agenus Inc. (AGEN) Q4 2023 Results Conference Call March 14, 2024 08:30 AM ET Company Participants Zack Armen - Head of Investor Relations Garo Armen - Chairman and Chief Executive Officer Steven O'Day - Chief Medical Officer Christine ...
News, Short Squeeze, Breakout and More Instantly...
Extended BOT/BAL Therapy Yields Pronounced Improvements in Tumor Reductions Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced results from an investigator-sponsored trial (IST) of botensilim...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced that the Cancer Therapy Evaluation Program (CTEP) is accepting Letters of Intent (LOIs) to conduct clinical studies using botensilimab (BOT), a huma...
2024-06-27 01:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...